Ivan Kairatov is a leading biopharma expert specializing in the research and development of next-generation immunotherapies. With a deep background in genetic engineering and tumor immunology, he has focused his career on solving the spatial and metabolic challenges that prevent modern medicine
The global biopharmaceutical landscape experienced a seismic shift on March 23, 2026, when the industry leader Sanofi finalized a worldwide exclusive licensing agreement with the innovative biotech firm Kali Therapeutics. This strategic alliance centers on the development of KT501, a sophisticated
The field of pediatric surgery is currently witnessing a paradigm shift, moving away from purely mechanical repairs toward the biological reconstruction of complex organs. For children born with long-gap esophageal atresia, the challenge has always been the physical impossibility of connecting two
Modern oncology is currently witnessing a profound shift as the mechanical precision of protein engineering finally catches up to the complex biological reality of the human immune system. For years, the promise of T-cell engagers (TCEs) was restricted to blood-borne malignancies where the targets
The current landscape of biological production is frequently hampered by a fundamental misalignment between the engineering of high-performing microbial strains and the logistical realities of industrial-scale purification processes. This systemic failure often manifests when a strain that performs
The landscape of modern medicine is currently shifting as BioNTech SE initiates a monumental transformation by separating its core operations into two distinct entities. This strategic pivot involves the launch of an independent biotechnology firm that will focus exclusively on pioneering